Cargando…
Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada
BACKGROUND: Ovarian cancer is a leading cause of cancer-related mortality. Although the disease is relatively rare, it carries a disproportionately large morbidity burden. OBJECTIVE: We conducted a cost-utility analysis from a Canadian public payer perspective to determine the cost effectiveness of...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5820234/ https://www.ncbi.nlm.nih.gov/pubmed/29464667 http://dx.doi.org/10.1007/s41669-017-0030-7 |